50,000 heart patients enrolled in Real-World stent study

NCT ID NCT01788592

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study is tracking 50,000 people with coronary artery disease who receive drug-eluting stents during a routine procedure to open blocked heart arteries. Researchers want to see how well these stents prevent major heart problems like death, heart attack, or the need for another procedure. The goal is to understand how these stents perform in everyday practice, not just in controlled trials.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

drug-eluting stent

What this could lead to

If successful, this study could confirm that drug-eluting stents are safe and effective for routine use in a broad range of patients with coronary artery disease.

What could go wrong

This is an observational study, not a randomized trial, so results may be influenced by patient selection. It does not test a new treatment, only evaluates existing practice.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CORONARY ARTERY DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

coronary artery disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Asan Medical Center

    RECRUITING

    Seoul, South Korea

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact